Thinle Chodon to Cell Line, Tumor
This is a "connection" page, showing publications Thinle Chodon has written about Cell Line, Tumor.
Connection Strength
0.160
-
A rare population of tumor antigen-specific CD4+CD8+ double-positive aß T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. J Immunother Cancer. 2019 01 09; 7(1):7.
Score: 0.026
-
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014 Jul 01; 20(13):3446-57.
Score: 0.019
-
Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014 May; 2(5):459-68.
Score: 0.018
-
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79.
Score: 0.018
-
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93.
Score: 0.018
-
Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother. 2013 Feb; 36(2):102-11.
Score: 0.017
-
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724.
Score: 0.016
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7.
Score: 0.015
-
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010 Sep; 136(3):338-47.
Score: 0.014